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Prostate cancerWe have previously described the development of novel sterically stabilized F3-targeted pH-sensitive lip-
osomes, which exhibited the ability to target both cancer and endothelial cells. Herein, the therapeutic
potential of those liposomes was assessed upon encapsulation of a siRNA against a well-validated molec-
ular target, PLK1.
Treatment of prostate cancer (PC3) and angiogenic endothelial (HMEC-1) cells with F3-targeted lipo-
somes containing anti-PLK1 siRNA resulted in a significant decrease in cell viability, which was mediated
by a marked PLK1 silencing, both at the mRNA and protein levels. Furthermore, pre-treatment of PC3 cells
with F3-targeted liposomes containing anti-PLK1 siRNA enabled a 3-fold reduction of paclitaxel IC50 and a
2.5-fold augment of the percentage of cancer cells in G2/mitosis arrest, which ultimately culminated in
cell death.
Overall, the F3-targeted nanocarrier containing an anti-PLK1 siRNA might constitute a valuable system
for prostate cancer treatment, either applied in a single schedule or combined with conventional
chemotherapy.
 2013 Elsevier B.V. All rights reserved.1. Introduction effects due to unspecific accumulation in healthy organs. Addition-Prostate cancer is a highly prevalent disease and the second
most common cancer among males in developed countries, being
the sixth leading cause of cancer-related death in men [1]. Conven-
tional anti-prostate cancer therapies include surgery, hormonal
ablation, radiation, immunotherapy, and chemotherapy. Despite
increasing efforts, these therapies are yet to be effective in patients
with locally advanced and/or metastatic disease [2]. Moreover, cur-
rent available chemotherapies often result in dose-limiting sideally, induction of resistance to the chemotherapeutic agents is one
of the main reasons for treatment failures [3,4].
The better understanding of the different signaling pathways of
cancer cells and supportive stroma has allowed the identification
of numerous molecular targets whose downregulation can lead
to cell death, angiogenesis inhibition, or reversion of the malignant
phenotype [5,6]. This broad and deep knowledge provides the basis
for the rational design of novel therapeutic strategies envisaging
the modulation, at different cell levels within a tumor, of specific
signaling pathways that dictate tumor growth and aggressiveness.
Several reports have demonstrated that increased sensitivity to
chemotherapy can be achieved by targeting relevant molecular tar-
gets [7–9]. With this strategy, it is envisaged that improved clinical
outcomes will be achieved with lower drug doses and consequent
reduction of unwanted side effects. Furthermore, considering the
biological heterogeneity of a tumor, it is expected that a multi-tar-
geted therapy at the intracellular level may produce better thera-
peutic results.
Polo-like kinase 1 (Plk1) is a serine/threonine kinase that regu-
lates mitotic entry and progression. Its expression level in normal
tissues is very low or undetectable, but is overexpressed in a wide
variety of tumors [10], including prostate cancer [11], being often
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studies have suggested Plk1 as a marker of high risk of metastasis
formation [15,16]. Plk1 overexpression in cancer cells enables the
overriding of the cell cycle checkpoints, thus contributing for the
capability of cancer cells to proliferate in an uncontrolled manner,
even when DNA damage is present, which promotes chromosome
instability and aneuploidy [17]. It has been demonstrated that
downregulation of Plk1 leads to growth inhibition, mitotic arrest
and induction of apoptosis in cancer cell lines from different histo-
logical origins [11,18–20], and in vivo suppression of tumor growth
[19–22]. In contrast, Plk1 depletion in normal cells has not re-
vealed to be harmful, thus suggesting that treatment specificity
can be achieved when therapies that specifically modulate Plk1
are applied [20]. Recently, Plk1 downregulation was also correlated
with a significant decrease in the angiogenic network of a mouse
model of human colorectal carcinoma, thus indicating that Plk1
can have a pro-angiogenic effect [19]. Overall, Plk1 is a well-vali-
dated anti-cancer therapeutic target that might have impact at
two different levels within prostate cancer: the cancer cells and
the endothelial cells from angiogenic blood vessels.
One promising strategy to mediate gene downregulation is
undoubtly throughout RNA-interference molecules such as small-
interfering RNAs (siRNAs) [23,24]. However, the in vivo application
of these molecules faces numerous barriers such as degradation by
blood nucleases, internalization by the mononuclear phagocytic
system, rapid elimination by the kidneys, and limited internaliza-
tion by the target cells [25–27]. Therefore, their therapeutic appli-
cation is essentially dependent on the development of nanocarriers
that can mediate efficient siRNA delivery into the target cells.
We have previously described the development of sterically
stabilized F3-targeted pH-sensitive liposomes fulfilling the phys-
ico-chemical requisites demanded to a nanocarrier for systemic
delivery of siRNA [28]. As the F3 peptide is specifically internalized
by nucleolin, a receptor overexpressed on the surface of cancer and
endothelial cells from angiogenic tumor blood vessels [29], the
developed F3-targeted liposomes were internalized by both breast
cancer and HMEC-1 endothelial cells [28]. The developed F3-tar-
geted pH-sensitive liposomes incorporate in their composition the
fusogenic lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE), which has an inverted cone-shape, and its stabilizer cho-
lesteryl hemisuccinate (CHEMS). At physiological pH, an organized
and stable lipid bilayer is formed. However, under the acidic condi-
tions of the endocytic pathway, CHEMS is protonated, loosing its
ability to stabilize the inverted cone-shape of DOPE and thus leading
to the destabilization of the liposomal membrane. Such destabiliza-
tion favors the release of the encapsulated siRNA into the cell cyto-
plasm, which was indeed correlated with an efficient silencing of a
reporter gene (enhanced Green Fluorescent Protein, eGFP) [28]. In
addition, the developed F3-targeted pH-sensitive liposomes were
stable and biocompatible with blood and no signs of toxicity were
observed upon multiple systemic administrations [28].
Therefore, the goal of this work was to evaluate the potential of
the previously developed dual-targeted nanoplatform for the
delivery of siRNA against a relevant therapeutic target (PLK1) to
prostate cancer and endothelial cells, and its role in the chemosen-
sitization of cancer cells to paclitaxel.2. Materials and methods
2.1. Materials
1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-distea-
royl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE), N-Palmitoyl-Sphingosine-1-[Suc-
cinyl(MethoxyPolyethylene Glycol)2000] (C16-Ceramide mPEG2000),1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-
N-[Maleimide (Polyethylene Glycol)2000] ammonium salt (DSPE-
PEG-MAL), and L-a-Phosphatidylethanolamine-N-(lissamine
rhodamine B sulfonyl) (Rho-PE) were purchased from Avanti Polar
Lipids (USA). The lipids, cholesterol (CHOL) and cholesteryl hemi-
succinate (CHEMS), were obtained from Sigma (Germany).
The anti-PLK1 siRNA (antisense sequence 50-GUAAAGAA CUC-
GUCAUUAAGCdTdT-30) and the non-specific control siRNA (CTR
siRNA) (antisense sequence 50-ACGUGACACGUUCGGAGAAdTdT-
30) were synthesized by Dharmacon (USA). The F3 peptide
(KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK) and the non-specific
(NS) peptide (ARALPSQRSR) were synthesized by Genecust
(Luxembourg).2.2. Cell lines
The human prostate cancer cell line, PC3, was purchased from
American Type Culture Collection (ATCC). The human microvascu-
lar endothelial cell line, HMEC-1, was a generous gift from the Cen-
ter for Disease Control and Prevention (USA). PC3 cells were
cultured in RPMI 1640 medium (Sigma, Germany) supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (Invitrogen,
USA), 100 U/ml penicillin, and 100 lg/ml streptomycin (Invitrogen,
USA). HMEC-1 cells were cultured in RPMI 1640 supplemented
with 10 ng/ml of mouse epidermal growth factor (mEGF) (Sigma,
Germany) and 1 lg/ml hydrocortisone (Sigma, Germany). Cells
were maintained at 37 C, in a 90% humidified atmosphere, con-
taining 5% CO2. Cells were maintained in the exponential growth
phase and used at a low passage number. All the experiments
involving the mentioned cells were conducted in medium contain-
ing 10% of serum.2.3. Preparation of sterically stabilized liposomes
Encapsulation of siRNA into sterically stabilized liposomes was
preformed as previously described [28]. Briefly, a lipid mixture of
DOTAP/DSPC/DOPE/CHOL/CHEMS/CerC16PEG2000, (25:10:25:26:10:4
mol%, relative to total lipid) in absolute ethanol was added to the
anti-PLK1 siRNA, or the control (CTR) siRNA, in 20 mM citrate buf-
fer, pH 6, previously heated at 65 C.
The resulting particles were then extruded 21 times through
polycarbonate membranes of 100 nm pore diameter, using a Lipos-
oFast basic extruder (Avestin, Canada). Removal of ethanol and
non-encapsulated siRNA was carried out upon running the ex-
truded nanoparticles through a Sepharose CL-4B column equili-
brated with HEPES buffered saline (HBS) (20 mM HEPES, 145 mM
NaCl), pH 7.4. Targeted liposomes were prepared by the post-inser-
tion method [30]. Briefly, thiolated F3 peptide or NS peptide were
first coupled to DSPE-PEG-MAL micelles, prepared in MES buffered
saline (MBS) (20 mM MES, 20 mM HEPES), pH 6.5. Insertion of
DSPE-PEG-MAL-F3 or DSPE-PEG-MAL-NS conjugates onto the pre-
formed sterically stabilized liposomes took place upon incubation
of the latter with the corresponding micelles at 50 C for 1 h. For
the non-targeted lipid particles, post-insertion was performed only
with plain DSPE-PEG-MAL micelles.
The resulting F3-targeted liposomes were characterized by a
mean size of 146.13 ± 2.96 nm, a polydispersity index of 0.148
± 0.05, a zeta potential close to the neutrality (1.94 ± 7.06 mV),
and an encapsulation efficiency of 75.80 ± 15.07%. Freeze-fracture
electron microscopy clearly indicated that the F3-targeted lipo-
somes containing the anti-PLK1 siRNA were spherical vesicles (data
not shown).
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Two hundred and fifty thousand of PC3 cells were seeded in 48-
well plates. Twenty-four hours later, cells were incubated at 37 C
during 1 h, with rhodamine-labeled F3-targeted, NS-targeted, or
non-targeted liposomes at 0.2, 0.4, or 0.6 mM of total lipid. After-
ward, cells were washed three times with phosphate buffer saline
(PBS) pH 7.4, detached, and immediately analyzed by flow cytom-
etry using a FACS Calibur flow cytometer (BD, Biosciences). Rhoda-
mine fluorescence was evaluated in the FL2 channel, and a total of
20.000 events were collected. Data were analyzed with the Cell
Quest Pro software.
2.5. Assessment of cell viability
In order to evaluate the impact on cell viability of different lipo-
somal formulations containinganti-PLK1 siRNA,25.000PC3prostate
cancer cells were seeded in 24-well plates. Twenty-four hours later,
cellswere transfectedwith either anti-PLK1 siRNA (100 nMto2 lM)
encapsulated in F3-targeted or non-targeted liposomes, or with the
CTR siRNA encapsulated in the former, at 37 C during 8 h. After-
ward, the culturemediumwas replaced by freshmedium and a sec-
ond transfection was performed 40 h after the first treatment.
Ninety-six hours after the beginning of the experiment (40 h after
the second transfection), cell viability was evaluated using the Res-
azurin reductionmethod. Briefly, cells were incubated, at 37 C dur-
ing 2 h, with 10% of resazurin dye in culture medium, followed by
absorbance measurements at 540 nm (reduced form) and 630 nm
(oxidized form) in a microplate fluorimeter Microdevices Spectra-
Max Gemini EM. Cell viability was extrapolated from the resazurin
reduction using the following equation: [(eoxi630  A540  eoxi540
 A630)treated cells/(eoxi630  A540  eoxi540  A630)untreatedcells]  100.
2.6. Quantification of PLK1 mRNA by quantitative real-time reverse-
transcription PCR (qRT-PCR)
Using the same experimental conditions mentioned in the pre-
vious section, PLK1 mRNA was assessed 24 h after the second
transfection (72 h after the beginning of the experiment) by qRT-
PCR.
Cells were harvested and RNA extracted with Quick-RNAMicro-
Prep (Zymo Research, Germany) according to the manufacturer’s
instructions. The Quanti-iT™ Ribogreen (Invitrogen, USA) reagent
was used to quantify the extracted RNA. Then, 0.5 lg of RNA was
reversed transcribed into cDNA using the QuantiTec Reverse Tran-
scription kit (Qiagen, Germany) following manufacturer’s
instructions.
Quantitative real-time PCR (qPCR) was performed using the
Iq™SYBR Green Supermix (Bio-Rad, USA). Beta-2-microglobulin
(b2M) was used as the endogenous control (housekeeping gene).
The forward primer for b2M was 50-GAGTATGCCTGCCGTGTG-30
and the reverse primer was 50-AATCCAAATGCGGCATCT-30 (Micros-
ynth, Switzerland). For PLK1, the QuantiTect™ Primer Assay (Qia-
gen, Germany) was used.
The optimized qPCR conditions included the activation of DNA
HotStartTaq Plus DNA polymerase followed by 40 cycles of two
steps: a first step of denaturation (10 s at 95 C) and a second step
of combined annealing/extension (30 s at 60 C). After the qPCR, a
melting curve analysis of the PCR products was performed to con-
firm their specificity.
The threshold cycle (Ct) values were generated by the iQ5 Opti-
cal System Software. The level of PLK1mRNA was calculated by the
Livak method, 2DDCt  100, where DDCt = (Ct PLK1  Ct
b2M)treated  (Ct PLK1  Ct b2M)untreated. The application of this
method relies on the similar PCR efficiencies between the target
gene and the housekeeping gene.2.7. Evaluation of Plk1 protein by Western blot
Using the same experimental conditions mentioned in the pre-
vious section, Plk1 protein was evaluated by Western blot 48 h
after the second transfection (96 h after the beginning of the
experiment).
Protein extracts were obtained from PC3 cells using a lysis buf-
fer (10 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100)
containing a protease inhibitor cocktail (Roche, USA) and submit-
ted to 3 freeze–thaw cycles. After centrifugation, protein content
was separated and quantified using the BCA™ Protein Assay Kit
(Pierce, USA). Then, 20 lg of total protein was resuspended in load-
ing buffer (0.0625 mM Tris HCl, 25% glycerol, 4% sodium dodecyl
sulfate, 0.01% bromophenol blue, 5% beta-mercaptoethanol), incu-
bated for 5 min at 95 C and loaded onto a 10% resolving SDS–poly-
acrylamide gel. After electrophoresis (100 V for approximately
1.5 h), proteins were transferred onto a polyvinylidene difluoride
(PVDF) membrane (GE Healthcare Amersham Hybond™-P, UK),
which had been previously incubated with a blocking solution con-
taining 5% of non-fat milk, during 1 h at room temperature. The
membrane was further incubated with a monoclonal antibody
anti-Plk1 (Sigma, Germany), overnight at 4 C, followed by incuba-
tion with the appropriate secondary antibody linked to alkaline
phosphatase (GE Healthcare, Sweden), for 1 h at room tempera-
ture. After incubation, the membrane was washed and incubated
with ECF (alkaline phosphatase substrate) (GE Healthcare, Sweden)
for 5 min. The protein bands were detected by chemifluorescence
in a VersaDoc Imaging System (Bio-Rad, USA). The analysis of band
intensity was performed using the Quantity One software (Bio-Rad,
USA).
Equal protein loading was shown by reprobing the membrane
with an anti-actin antibody (Sigma, Germany) and with the appro-
priate secondary antibody.
2.8. Sensitization of PC3 cells to paclitaxel
Twenty-five thousand PC3 cells were seeded in 48-well plates
and transfected 24 h later with either anti-PLK1 siRNA encapsu-
lated in F3-targeted or non-targeted liposomes, or with the CTR
siRNA encapsulated in the former, at a final siRNA concentration
of 1 lM. After 8 h of incubation at 37 C, the cultured medium
was replaced by fresh medium.
Incubation with paclitaxel was performed 40 h after the trans-
fection with the developed liposomes, for 24 h at 37 C. The cell
culture medium was then replaced with fresh one, and at 96 h, cell
viability was assessed by the resazurin reduction method, as previ-
ously described. In order to evaluate the impact of the sequential
treatment in the overall cell viability, control cells were solely
incubated with culture medium (untreated cells).
The required paclitaxel concentration to promote 50% reduction
of cell viability (IC50) was determined by a non-linear regression
assuming sigmoidal dose–response. The paclitaxel’s dose reduction
index (DRI) achieved upon pre-incubation with the different lipo-
somal formulations was based on the ratio of IC50 of paclitaxel
determined when used alone and when combined with the
liposomes.
2.9. Cell cycle analysis by flow cytometry
The effect of liposomal anti-PLK1 siRNA and/or paclitaxel on cell
cycle distribution of PC3 cells was evaluated, using the same exper-
imental conditions mentioned in the previous section. After incu-
bation, cancer cells were fixed in 70% ethanol during 2 h at 4 C
and then washed with PBS and labeled with 7-amino-actinomycin
D (7-AAD) (Sigma, Germany) at 4 C for 30 min. In the analysis per-
formed by flow cytometry using a FACS Calibur flow cytometer
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AAD fluorescence was evaluated in the FL3 channel. Cell cycle anal-
ysis was performed with ModFit LT software.
2.10. Statistical analysis
The results are presented as the mean ± standard deviation (SD)
of at least 3 independent experiments, each one with triplicates.
Two-way ANOVA with Bonferroni’s post-test was used to deter-
mine statistically significant differences of the means between
multiple groups. Statistical differences were presented at probabil-
ity levels of p > 0.05, p < 0.05, p < 0.01 and p < 0.001.
3. Results
3.1. Cellular association studies
Within the range of the tested concentrations, the attachment
of the F3 peptide to the liposomal surface led to a 7- to 11-fold
improvement on the extent of PC3 cellular association, when com-
pared with the non-targeted liposomes or liposomes targeted by a
non-specific peptide. The extent of cellular association for the F3-
targeted liposomes was clearly dependent on the lipid concentra-
tion (Fig. 1A). The narrow shape of the histograms generated by
flow cytometry demonstrated that the F3-targeted liposomes
bound to the bulk PC3 cells in a similar extent, indicating that a
homogenous cellular association was achieved (Fig. 1B).
3.2. Effect of F3-targeted liposomes containing an anti-PLK1 siRNA on
cancer and endothelial cells viability
Plk1 has been suggested as a promising molecular target since
its downregulation results in mitosis arrest, proliferation inhibi-
tion, cancer cell death, as well as in vivo tumor growth inhibition
[10]. Therefore, aiming at evaluating the therapeutic potential of
the developed F3-targeted nanotechnology-based strategy, a siRNA
against PLK1 was designed and encapsulated in the mentioned
liposomes.
Cell proliferation studies demonstrated that F3-targeted lipo-
somes, entrapping the anti-PLK1 siRNA, produced a significant
anti-proliferative effect and in a dose-dependent manner in both
prostate cancer (Fig. 2A) and endothelial cells from angiogenic
blood vessels (Fig. 2B). At 2 lM of anti-PLK1 siRNA, PC3 and
HMEC-1 cell viability decreased 57.0 ± 9.03% and 39.4 ± 9.86%,
respectively. On the other hand, the non-targeted counterpart didFig. 1. Extent of cellular association of rhodamine-labeled liposomes with human pro
rhodamine-labeled F3-targeted, targeted by a non-specific peptide and non-targeted lipo
cytometry. Bars are the mean ± SD of 3 independent experiments. Two-way ANOVA ana
referenced samples and the F3-targeted liposomes (p < 0.001). B) Representative his
0.4 mM of total lipid) with PC3 cells, upon incubation at 37 C during 1 h.not have significant effects on the viability of both those cells,
which is in accordance with its residual cellular association previ-
ously observed. Taken together, these results have clearly demon-
strated that the presence of the F3 peptide on the liposomal surface
strongly contributed to improve the cytotoxicity of an anti-PLK1
siRNA, through its ability to mediate an effective interaction with
the target cells. In the case of HMEC-1 cells, the observed effect
encompassed a certain extent of non-specific effects, as revealed
by the experiments carried out with F3-targeted liposomes con-
taining the control siRNA (Fig. 2B). This result is in accordance with
other reports, where it was demonstrated that different siRNA se-
quences, regardless of their target, can have anti-angiogenic effects
[31,32].
3.3. Assessment of PLK1 mRNA and protein levels
In order to confirm that the decrease in PC3 cell viability was
due to PLK1 downregulation, the levels of PLK1 mRNA and protein
were assessed by qRT-PCR and Western blot, respectively. In fact,
following incubation with F3-targeted liposomes entrapping anti-
PLK1 siRNA, at 100 nM to 2 lM, a 33.92 ± 7.60 to 59.74 ± 5.07%
PLK1 mRNA reduction was observed, showing that this liposomal
formulation was 1.8- to 2.3-fold more effective than the non-tar-
geted counterpart. In addition, no significant reduction on the
mRNA levels was reached with the control siRNA, indicating that
the observed PLK1 downregulation was sequence-specific
(Fig. 3A). In parallel experiments, the same trend was observed
at the level of protein downregulation. Incubation of PC3 cells with
F3-targeted liposomes containing anti-PLK1 siRNA promoted a sig-
nificant reduction in the protein levels, approximately 25% at
500 nM and 50% at 2 lM of siRNA (Fig. 3B and C). In contrast, no
effect on Plk1 protein level was observed upon incubation with
non-targeted liposomes containing anti-PLK1 siRNA or with F3-tar-
geted liposomes entrapping the control siRNA.
3.4. Sensitization of PC3 cells to paclitaxel upon pre-treatment with
F3-targeted liposomes containing an anti-PLK1 siRNA
The anti-proliferative effect of the sequential treatment of PC3
cells with the developed F3-targeted liposomes containing anti-
PLK1 siRNA and free paclitaxel was assessed. Free paclitaxel, within
the range of 1.56–6.25 nM, had an anti-proliferative effect from
2.35 ± 4.46 to 24.80 ± 5.80%. Treatments with F3-targeted lipo-
somes containing anti-PLK1 siRNA, followed by free paclitaxel
within the above-mentioned range, reduced cell viability fromstate cancer (PC3) cells. (A) Cells were incubated with different concentrations of
somes, at 37 C during 1 h. After incubation, rhodamine signal was assessed by flow
lysis of variance with Bonferroni’s post-test was used for comparisons between the
togram of the association pattern of F3-targeted and non-targeted liposomes (at
Fig. 2. Effect of different liposomal formulations containing anti-PLK1 siRNA on the viability of cancer and endothelial cells. (A) PC3 and (B) HMEC-1 cells were transfected at
0 h and at 48 h, with either anti-PLK1 siRNA encapsulated in F3-targeted or non-targeted liposomes, or with the CTR siRNA encapsulated in the former. Cell viability was
accessed by the Resazurin reduction assay 96 h after the beginning of the experiment. Bars are the mean ± SD of 4 or 6 independent experiments for HMEC-1 or PC3 cells,
respectively. Two-way ANOVA analysis of variance with Bonferroni’s post-test was used for comparisons between the referenced samples and the F3-targeted liposomes
containing the anti-PLK1 siRNA (p < 0.001; p < 0.01; no symbol p > 0.05).
Fig. 3. Effect of liposomal anti-PLK1 siRNA on PLK1 mRNA and protein levels in PC3 prostate cancer cells. PC3 cells were transfected at 0 and 48 h, with anti-PLK1 siRNA
encapsulated in either F3-targeted or non-targeted liposomes, or with the control siRNA encapsulated in the former. (A) PLK1 mRNA levels were assessed 24 h after the
second transfection by qRT-PCR. (B) Total protein was collected 48 h after the second transfection for evaluation of Plk1 protein levels by Western blot. Bars represent the
mean ± SD of 3 or 5 independent experiments for mRNA or protein, respectively. Two-way ANOVA analysis of variance with Bonferroni’s post-test was used for comparisons
with the F3-targeted liposomes containing the anti-PLK1 siRNA (p < 0.001; p < 0.01, p < 0.05; no symbol p > 0.05). (C) Representative Western blot for Plk1 protein levels
in PC3 cells following two transfections with different liposomal formulations, bands 1–2: non-targeted at 1 and 2 lM anti-PLK1 siRNA, respectively; bands 3–4: F3-targeted
at 1 and 2 lM anti-PLK1 siRNA, respectively; band 5–6: F3-targeted at 1 and 2 lM CTR siRNA, respectively; and band 7: untreated cells.
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non-targeted liposomes containing anti-PLK1 siRNA or F3-targeted
liposomes containing a non-specific siRNA and paclitaxel also en-
hanced cell death, albeit the differences were not statistically sig-
nificant when compared with the drug alone (p > 0.005). For
paclitaxel concentrations higher than 6.25 nM, no significant
improvements were achieved with the liposomal pre-treatments
as a high anti-proliferative effect was already observed upon treat-
ments with only the free drug (Fig. 4).
It was then evaluated whether the sequential treatment with
the different liposomal formulations and paclitaxel could actually
result in increased paclitaxel’s sensitivity. Pre-treatment of PC3
cells with F3-targeted liposomes containing anti-PLK1 siRNA de-
creased paclitaxel’s IC50 from 9.07 ± 1.58 to 2.82 ± 0.58 nM.
Although reduction of paclitaxel’s IC50 was also achieved with
pre-treatments with non-targeted liposomes containing anti-
PLK1 siRNA (5.19 ± 0.54 nM) or F3-targeted liposomes containing
the non-specific siRNA (4.92 ± 0.63 nM) (Table 1), the highest DRI(3.22) was attained with the F3-targeted liposomes containing
anti-PLK1 siRNA (Table 1). These results supported our hypothesis
that the developed F3-targeted nanotechnology-based strategy
entrapping a siRNA targeting a cancer-relevant molecular target
might have beneficial effects in oncology, both in single and com-
bined treatments.
3.5. Cell cycle analysis
To gain further insights into the cellular effects of the sequential
treatments of F3-targeted liposomes entrapping anti-PLK1 siRNA
with paclitaxel, cell cycle distribution was analyzed.
Single treatments of PC3 cells with 6.25 nM paclitaxel did not
affect the cell cycle distribution, showing 20–30% of cells in G2/M
phase (Fig. 5A and D). Pre-treatment with F3-targeted liposomes
containing anti-PLK1 siRNA, followed by exposure to the free drug,
increased the percentage of cells in G2/M phase to 70% (Fig. 5F),
which corresponded to 2.5- or 3-fold increase relative to cells
Fig. 4. Effect of sequential treatment with liposomes containing anti-PLK1 siRNA and free paclitaxel on the viability of PC3 cells. PC3 cells were transfected at 0 h, with anti-
PLK1 siRNA encapsulated in either F3-targeted or non-targeted liposomes, or with the CTR siRNA encapsulated in the former. Forty hours after transfection with the different
liposomal formulations, PC3 cells were incubated with paclitaxel. Cells only incubated with cell culture medium were used as controls. Cell viability was determined 24 h
after the paclitaxel incubation period, using the resazurin reduction assay. Bars represent the mean ± SD of 3 independent experiments. Two-way ANOVA analysis of variance
with Bonferroni’s post-test was used to compare the treatment with paclitaxel alone with the sequential treatment (p < 0.001; p < 0.01, p < 0.05 and no symbol p > 0.05).
Table 1
Effect of pre-treatments with different liposomal formulations of anti-PLK1 siRNA on paclitaxel’s IC50 and DRI.
Paclitaxel alone F3-targeted Non-targeted F3-targeted
(anti-PLK1 siRNA) + paclitaxel (anti-PLK1 siRNA) + paclitaxel (CTR siRNA) + paclitaxel
IC50 (nM) 9.07 ± 1.58 2.82 ± 0.58### 5.19 ± 0.54##** 4.92 ± 0.63##**
DRI – 3.22 1.75 1.84
PC3 cells were incubated with paclitaxel, either alone or following transfection with the different liposomal formulations. Chemosensitization to paclitaxel was assessed upon
normalization of the results to PC3 cells solely treated with the same concentration of the corresponding liposomal formulation of anti-PLK1 siRNA. Each value represents the
mean ± SD of 3 independent experiments. One-way ANOVA analysis of variance with Dunnett’s post-test was used.
### p < 0.001 when the comparison was between the treatment with paclitaxel alone and the sequential treatments.
## p < 0.01.
** p < 0.01, when the comparison was established between the pre-treatment with F3-targeted liposomes containing anti-PLK1 siRNA and the pre-treatments with the other
control formulations.
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contrast, sequential treatments with the non-targeted counterpart
resulted only in a minor increase in the number of cells in G2/M
phase (Fig. 5E). In addition, the same concentration of the control
siRNA entrapped in F3-targeted liposomes alone, or in combination
with paclitaxel, did not alter the cell cycle distribution significantly
(data not shown).
Although it has been described that PLK1 silencing by itself in-
duces cell cycle arrest [11,18], PC3 cells treated solely with F3-tar-
geted liposomes containing anti-PLK1 siRNA did not demonstrate a
considerable increase in the G2/M phase (Fig. 5C). This result can
be explained by the long time between the liposomal treatment
(at time 0 h) and the cell cycle evaluation (at 96 h), which may
have allowed the recovery of Plk1 levels.4. Discussion
Despite prostate cancer death rates have been decreasing in
many developed countries due to its detection at early stages as
well as improved treatment options, recurrence and formation of
distant metastasis are still serious problems that regularly end in
morbidity [1]. Moreover, severe side effects and appearance of
drug resistance are serious limitations of common chemotherapeu-
tic drugs [3,4]. Therefore, novel therapeutic strategies with im-
proved molecular and cellular specificity are urgently needed. In
this respect, RNA-interference molecules, such as siRNA, mightconstitute a new strategy for cancer treatment taking advantage
of their ability to downregulate gene expression.
However, their translation to the clinical set has been limited by
the lack of a proper delivery system capable of mediating effective
delivery to distant sites of disease, as solid tumors, following intra-
venous administration [25–27]. As an attempt to overcome this
major drawback, we have previously developed a F3-targeted
pH-sensitive lipid-based nanoparticle for siRNA delivery toward
cancer and endothelial cells from angiogenic tumor blood vessels
[28]. Aiming at assessing the true therapeutic relevance of the
developed targeted nanosystem, an anti-PLK1 siRNA was designed
and encapsulated in the former.
Cellular association studies showed that the F3-targeted lipo-
somes were efficiently internalized by PC3 cells in a homogenous
manner (Fig. 1), which is in accordance with the internalization
pattern observed for these F3-targeted liposomes in both human
breast cancer and endothelial cells from angiogenic blood vessels,
HMEC-1 cells [28,33].
Treatment of PC3 and HMEC-1 cells with F3-targeted liposomes
entrapping anti-PLK1 siRNA produced a significant decrease in cell
viability in a lipid concentration-dependent manner, in contrast
with the non-targeted counterpart (Fig. 2). These results were
likely the consequence of combining in the same technological
platform, a component of targeting an internalizing receptor with
intracellular triggered release of siRNA [28]. Moreover, targeting
angiogenesis, in addition to cancer cells, might be of high impor-
tance as tumor growth and metastasis formation are highly depen-
dent on the angiogenic process [34].
Fig. 5. Cell cycle distribution upon single or sequential treatments with liposomal anti-PLK1 siRNA and paclitaxel. (A) Untreated cells. (B) Cells treated with 1 lM of anti-PLK1
siRNA encapsulated in non-targeted liposomes or (C) in F3-targeted liposomes. (D) Cells treated with 6.25 nM of free paclitaxel. (E) Alternatively, cells treated with 6.25 nM of
free paclitaxel upon pre-treatment with 1 lM of anti-PLK1 siRNA encapsulated in non-targeted liposomes or (F) in F3-targeted liposomes. In all treatments, DNA was stained
with 7-AAD and cell cycle analyzed by flow cytometry. The results shown are from a representative experiment.
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ies reporting decrease in cancer cell viability upon siRNA-mediated
Plk1 downregulation. However, most of those studies have used
positively charged transfection reagents to mediate the siRNA
delivery into the target cells [7,8,11,18,35], which represents a
valuable strategy for in vitro purposes but not for in vivo applica-
tions [36]. In fact, upon intravenous administration, positively
charged nanoparticles interact with the negatively charged serum
proteins forming aggregates that are mainly accumulated in the
lungs, liver, and spleen [37]. Moreover, cationic liposomes often in-
duce severe pulmonary toxicity [36]. For these reasons, the in vivo
use of this class of nanoparticles has been limited to local admin-
istration. In the work of Nogawa et al. [22], intravesical administra-
tion of an anti-PLK1 siRNA, complexed with cationic liposomes,
effectively prevented the growth of bladder cancer in an orthotopic
mouse model. However, this strategy is not feasible when a well
established tumor with distant metastasis has to be treated.
To gain further insights into the cellular effects of F3-targeted
liposomes entrapping anti-PLK1 siRNA, PLK1 mRNA and protein
levels were evaluated. Downregulation at these two levels was
achieved only when anti-PLK1 siRNA was delivered by the F3-tar-
geted liposomes, but neither by the non-targeted counterpart nor
by the control siRNA delivered by the former (Fig. 3). These obser-
vations indicated that the observed decrease in cell viability was
correlated with a RNA interference-mediated mechanism.
Although siRNA by itself can bring benefits for cancer treat-
ment, a multi-targeted strategy at the cellular and intracellular le-
vel may lead to better clinical outcomes. Furthermore, the use of
siRNA to inhibit cancer-relevant molecular targets has been
explored as a valuable strategy to enhance chemosensitivity of
cancer cells [9,38,39].Paclitaxel is a microtubule-stabilizing agent leading to mitotic
arrest and further cell death, which has been used for the treat-
ment of a wide range of tumors including prostate cancer. Previous
reports [7,8] have shown that treatment of breast cancer cells with
siRNA targeting PLK1, delivered by cationic reagents, improved cell
sensitivity to paclitaxel, in a synergistic or additive manner,
depending on the cell line. Therefore, combination of drugs target-
ing cell cycle, which act by different mechanisms, would be ex-
pected to produce significant clinical benefits. This has led us to
assess the effect of combining F3-targeted liposomes encapsulating
anti-PLK1 siRNA and free paclitaxel on the viability of PC3 prostate
cancer cells.
Pre-treatment of cancer cells with anti-PLK1 siRNA encapsu-
lated in F3-targeted liposomes followed by treatment with free
paclitaxel led to a significant decrease in IC50 of paclitaxel, from
9.07 ± 1.58 to 2.82 ± 0.58 nM (Table 1). The mechanism underlying
this sensitization effect was proposed by Spankuch et al. [7], who
hypothesized that Plk1 downregulation stabilized the attachment
of kinetochores to microtubules, contributing to an imbalance of
the spindle checkpoint, which increased the sensitivity to microtu-
bule-interfering drugs like paclitaxel. Moreover, as Plk1 has
numerous substrates that are involved in mitosis entry and pro-
gression as well as in microtubule dynamics, DNA replication,
chromosome dynamics and p53 regulation [40], it was expected
that Plk1 downregulation would lead to changes in the expression
of those regulators which together also contributed to render can-
cer cells more prone to the cytotoxic effect of paclitaxel.
Furthermore, cell cycle studies demonstrated that pre-treat-
ment of cells with F3-targeted liposomes encapsulating anti-PLK1
siRNA strongly potentiated the effect of paclitaxel since most cells
accumulated in the G2/M arrest, thus leading to subsequent cell
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liposomes, and in contrast to the non-targeted counterpart, could
be used to effectively deliver an anti-PLK1 siRNA and sensitize
prostate cancer cells to paclitaxel.5. Conclusion
In conclusion, the previously developed F3-targeted liposomes,
when encapsulating a siRNA against PLK1, had an important im-
pact on the cell viability of two sub-populations of a solid tumor:
the cancer cells and the endothelial cells from angiogenic tumor
blood vessels. Therefore, this multi-targeted strategy may consti-
tute a novel and valuable approach for the treatment of prostate
cancer. Moreover, its ability to sensitize cancer cells to paclitaxel
is of high importance as it can contribute to lower side effects
and resistance of cancer cells to paclitaxel. In addition, it is impor-
tant to emphasize that the relevance of this strategy is not limited
to prostate cancer. Different reports have demonstrated that Plk1
downregulation has an anti-proliferative effect on cancer cell lines
of different histological origins [7,8,11,18,35]. Alongside, our group
has observed that F3-targeted liposomes can be specifically uptak-
en by several cancer cell lines of distinct origin, such as breast (hor-
mone-dependent and triple negative subtypes), colon, and small
cell and non-small cell lung cancer [41]. Therefore, it is anticipated
that the F3-targeted strategy herein described for Plk1 downregu-
lation can be successfully explored to tumors of diverse histologi-
cal origin.
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